We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App





New Technology that Detects MRSA in 15 Minutes Introduced at MEDLAB Middle East 2020

By LabMedica International staff writers
Posted on 06 Feb 2020
Print article
Image: The PCR ONE system (Photo courtesy of Scope Fluidics Group)
Image: The PCR ONE system (Photo courtesy of Scope Fluidics Group)
Scope Fluidics Group (Warsaw, Poland) presented its new PCR|ONE system at MEDLAB Middle East, one of the world’s major events in the field of medical diagnostics that was held in Dubai World Trade Center and attended by thousands of visitors from over 135 countries.

New technology and the latest innovations in laboratory medicine were the main focus of the inaugural Transformation Talks, taking place at MEDLAB Middle East held from February 3-6, 2020. In line with the show’s theme of Transforming tomorrow’s diagnostics, a range of new features were added to the 2020 edition of MEDLAB Middle East, including the Transformation Hub, where manufacturers had the opportunity to pitch their healthcare solutions to thousands of distributors.

Scope Fluidics introduced the PCR|ONE system to the participants of Transformation Talks at this year’s MEDLAB. The PCR|ONE is a 15-minute Point-Of-Care PCR for screening and syndromic testing that offers the world’s most rapid detection of bacteria and viruses – up to 20 different pathogens and drug resistance genes. The system is designed to analyze samples taken from a single patient in as little as 15 minutes, while its compact size makes it suitable for use in almost any medical practice or hospital admissions room.

“Technology is truly transforming medical diagnostics and healthcare and we are excited to take part in this process and contribute to faster and better access to information. This access to information is key to effective treatment because information allows for better formation of decisions. It saves lives and increases the comfort of patients and, ultimately, helps to reduce healthcare costs,” said Prof. Piotr Garstecki, CEO and Founder of Scope Fluidics Group. “The search and destroy policy urgently requires a rapid, accessible, and affordable diagnostic method than can be used in various settings. We believe PCR|ONE meets this crucial global need for a single-step method for rapidly and inexpensively identifying MRSA directly from nasal swabs.”

Related Links:
Scope Fluidics Group


Print article

Channels

Molecular Diagnostics

view channel
Image: Schematic representation of Chiari malformation type 1; it involves the lower part of the cerebellum known as tonsils, but not the brain stem (Photo courtesy of Healthline).

Common Brain Malformation Traced to Its Genetic Roots

About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. However about one in 10 of those children,... Read more

Industry

view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.